Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women - Full Text View

Sponsored by:	New York Downtown Hospital
Information provided by:	New York Downtown Hospital
ClinicalTrials.gov Identifier:	NCT00808522

Purpose

The purpose of the study is to evaluate whether hCG will result in a decrease in breast density.

High breast density has been associated with an increased risk in breast cancer. It has also been shown that decreasing density with a drug called tamoxifen has resulted in a decreased risk in breast cancer. The investigators are looking at the effect of hCG on breast density in people who are at increased risk of developing breast cancer and our theory postulates that through the hormonal actions of hCG and tamoxifen there would be a greater reduction in breast density in patients who are treated with hCG and tamoxifen versus patients treated with tamoxifen alone. Using this data the investigators will be able to hypothesize that the treatment of hCG will result in a reduction in breast cancer rates in the population and thus make available another drug which can be used to decrease the rates of breast cancer in the population

Condition	Intervention	Phase
Breast Cancer	Drug: hCG	Phase III

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

Drug Information available for: Tamoxifen Tamoxifen citrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Single Blind (Outcomes Assessor), Parallel Assignment
Official Title:	Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women.

Further study details as provided by New York Downtown Hospital:

Primary Outcome Measures:

The investigators will be looking at the mammographic breast density at the start of the trial and then every 6 months for 2 years. The treatment arm will have 30 injections of Hcg over a 60 day period. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Evaluation of breast cytology and serum hormone levels at 6 monthly intervals over the course of the study. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment:	84
Study Start Date:	December 2008
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
hCG: Experimental Patients at high risk for breast cancer will be treated with hCG	Drug: hCG recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
routine care: No Intervention Patients receiving routine care will be followed	Drug: hCG recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.

Detailed Description:

Pregnancy has been associated with a decreased risk of breast cancer. This has been reproduced in multiple studies and has been seen in multiple races.

People have been evaluating different hormones and practices associated with pregnancy to determine what factors reduce the risk of developing breast cancer in these patients. These pronounced findings have been evaluated in great detail by multiple scientists and one of the hormones which we think might be associated with a reduction in breast cancer is hCG. This statement has been backed by multiple studies which have looked at the direct effect of hCG on the growth and death of breast cancer cells in the lab and in animal models of breast cancer.

We want to determine if hCG is given to patients who are at increased risk of breast cancer will result in an accentuated decrease in breast cancer risk above and beyond the effect received by conventional breast cancer reducing protocols. Our final outcome in this study will be breast density on mammographic evaluation which is considered a marker for breast cancer. So our study will evaluate whether or not hCG will have an effect on the mammographic breast density.

After recruitment there will be two groups in our study an intervention group and non intervention group. In the intervention group patients would undergo a period of hCG injections which would last a total of 60 days and consist of 30 subcutaneous injections. The non intervention group will continue their conventional chemoprevention medication. Both groups will be followed for teo years and the images, cytology and blood samples will be sent to our labs for evaluation.

Eligibility

Ages Eligible for Study:	30 Years to 75 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

On tamoxifen therapy for the treatment or prevention of breast cancer.
Must have at least one remaining breast.

Exclusion Criteria:

Pregnant or nursing.
No history of allergic reactions to hCG.
Patients who have had bilateral mastectomies.
Uncontrolled thyroid disease.
Cognitively impaired and unable to consent for the trial.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00808522

Locations

United States, New York
New York Downtown Hospital	Recruiting
New York, New York, United States, 10038
Contact: Giuseppe Del Priore, MD, MPH 212-312-5268 nydresearch@downtownhospital.org
Sub-Investigator: Alan S Klapper, MD
Sub-Investigator: Steven Freidman, MD
Sub-Investigator: Joseph Bottino, MD
Sub-Investigator: Raffi Chalian, MD

Sponsors and Collaborators

New York Downtown Hospital

More Information

Responsible Party:	New Downtown Hospital ( Giuseppe Del Priore )
Study ID Numbers:	GD-10-08
Study First Received:	December 13, 2008
Last Updated:	December 15, 2008
ClinicalTrials.gov Identifier:	NCT00808522
Health Authority:	United States: Institutional Review Board

Keywords provided by New York Downtown Hospital:

Breast Cancer
Chemoprevention
Tamoxifen
Breast density
Hcg

Study placed in the following topic categories:

Skin Diseases
Breast Neoplasms
Tamoxifen
Breast Diseases

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 14, 2009